Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07300631

SpaceOAR Post-Market Registry Study

SpaceOAR Post-Market Registry Study — Recruiting • Oncology • NCT07300631.

📅 07 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07300631
Start
2025-12-31
Completion
2030-02
ClinicaliQ Trial Snapshot
  • SpaceOAR Post-Market Registry Study — Recruiting • Oncology • NCT07300631.
  • Registry study tracking short and long-term safety of rectal spacers used with radiotherapy for prostate cancer in UK and French patients.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Recently, concerns have been raised by regulators that there is little data about the long-term safety of rectal hydrogel spacers for use in conjunction with radiotherapy treatment for prostate cancer. To address this, this study will collect data about the short-term side-effects and long-term safety of SpaceOAR and SpaceOAR Vue rectal hydrogel spacers in men who receive them in the UK and France. Men who have agreed to receive these spacers as part of their standard medical care will be asked to take part in the study whereby data about…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Oncology · 16 Jul 2026
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not…
View guideline →
Clinical Brief
Advanced radiotherapy for prostate cancer to cut sessions from 20 to five
Oncology · BBC Health · 09 Jun 2026
Advanced hypofractionated radiotherapy for prostate cancer is now available on the NHS in England, reducing treatment from 20 sessions to 5 The…
View brief →
Guideline
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Oncology · 14 Jul 2026
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as…
View guideline →
Guideline
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)
Oncology · 18 Jun 2026
Imlunestrant evaluation was terminated – NICE did not complete appraisal of imlunestrant for oestrogen receptor-positive HER2-negative advanced breast cancer; clinicians should refer…
View guideline →
Guideline
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)
Oncology · 04 Jun 2026
Nogapendekin alfa inbakicept combined with BCG is no longer recommended for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ in the UK,…
View guideline →
Clinical Brief
Targeted prostate cancer treatment cuts risk of side effects, study suggests
Oncology · BBC Health · 16 Jul 2026
Focal therapy for prostate cancer demonstrates reduced side effects compared to whole-gland treatments, based on a decade-long NHS trial of 3,500 men,…
View brief →